Degron TherapeuticsDegron Therapeutics
Degron Therapeutics

Degron Therapeutics

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Website
2020Active24
Rate
Advertise here

About

Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases.

Technology stack

detected 2026-06-25
Emailunknown
Hosting
self_managed
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Degron Therapeutics do?

Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases. (formerly [].)

How much funding has Degron Therapeutics raised?

Degron Therapeutics has raised a total of $40M in funding. The most recent round on record is Series A Extension.

Where is Degron Therapeutics headquartered?

Degron Therapeutics is headquartered in San Diego, California, USA.

When was Degron Therapeutics founded?

Degron Therapeutics was founded in 2020.

What industry does Degron Therapeutics operate in?

Degron Therapeutics operates in Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare, Biotech, Clinical Trials.

How many employees does Degron Therapeutics have?

Degron Therapeutics has approximately 24 people on record.